JP7229169B2 - 生体高分子の精製のための超分子高アフィニティタンパク質結合系 - Google Patents

生体高分子の精製のための超分子高アフィニティタンパク質結合系 Download PDF

Info

Publication number
JP7229169B2
JP7229169B2 JP2019553971A JP2019553971A JP7229169B2 JP 7229169 B2 JP7229169 B2 JP 7229169B2 JP 2019553971 A JP2019553971 A JP 2019553971A JP 2019553971 A JP2019553971 A JP 2019553971A JP 7229169 B2 JP7229169 B2 JP 7229169B2
Authority
JP
Japan
Prior art keywords
antibody
peptide
binding
immunoamphiphile
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512385A5 (https=
JP2020512385A (ja
Inventor
ツイ ホンガン
リー イー
シュー シュアンクオ
リン ロック リー
リー チョンジエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020512385A publication Critical patent/JP2020512385A/ja
Publication of JP2020512385A5 publication Critical patent/JP2020512385A5/ja
Priority to JP2022168138A priority Critical patent/JP2023011689A/ja
Application granted granted Critical
Publication of JP7229169B2 publication Critical patent/JP7229169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/24—Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28023—Fibres or filaments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
JP2019553971A 2017-03-30 2018-03-28 生体高分子の精製のための超分子高アフィニティタンパク質結合系 Active JP7229169B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022168138A JP2023011689A (ja) 2017-03-30 2022-10-20 生体高分子の精製のための超分子高アフィニティタンパク質結合系

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478886P 2017-03-30 2017-03-30
US62/478,886 2017-03-30
PCT/US2018/024721 WO2018183417A1 (en) 2017-03-30 2018-03-28 A supramolecular high affinity protein-binding system for purification of biomacromolecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022168138A Division JP2023011689A (ja) 2017-03-30 2022-10-20 生体高分子の精製のための超分子高アフィニティタンパク質結合系

Publications (3)

Publication Number Publication Date
JP2020512385A JP2020512385A (ja) 2020-04-23
JP2020512385A5 JP2020512385A5 (https=) 2021-05-06
JP7229169B2 true JP7229169B2 (ja) 2023-02-27

Family

ID=63678187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553971A Active JP7229169B2 (ja) 2017-03-30 2018-03-28 生体高分子の精製のための超分子高アフィニティタンパク質結合系
JP2022168138A Pending JP2023011689A (ja) 2017-03-30 2022-10-20 生体高分子の精製のための超分子高アフィニティタンパク質結合系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022168138A Pending JP2023011689A (ja) 2017-03-30 2022-10-20 生体高分子の精製のための超分子高アフィニティタンパク質結合系

Country Status (6)

Country Link
US (3) US11359005B2 (https=)
EP (1) EP3601362A4 (https=)
JP (2) JP7229169B2 (https=)
KR (2) KR102660861B1 (https=)
CN (2) CN110741017B (https=)
WO (1) WO2018183417A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3601362A4 (en) * 2017-03-30 2020-12-16 The Johns Hopkins University HIGH AFFINITY PROTEIN SUPRAMOLECULAR BINDING SYSTEM FOR BIOMACROMOLECULES PURIFICATION
JP7379323B2 (ja) * 2017-08-18 2023-11-14 ザ・ジョンズ・ホプキンス・ユニバーシティ タンパク質精製のための超分子フィラメント集合体
US20210130395A1 (en) * 2018-05-11 2021-05-06 William Marsh Rice University Proximity induced site-specific antibody conjugation
CN114225020B (zh) * 2021-12-31 2023-05-02 暨南大学 一种ova淀粉样蛋白原纤维及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2006123829A1 (ja) * 2005-05-17 2006-11-23 Sapporo Medical University ＰＡＰ２ａに対する抗体ならびにその診断的および治療的使用
US8551781B2 (en) * 2009-11-19 2013-10-08 The Regents Of The University Of California Vault complexes for facilitating biomolecule delivery
EP3601362A4 (en) * 2017-03-30 2020-12-16 The Johns Hopkins University HIGH AFFINITY PROTEIN SUPRAMOLECULAR BINDING SYSTEM FOR BIOMACROMOLECULES PURIFICATION
JP7379323B2 (ja) * 2017-08-18 2023-11-14 ザ・ジョンズ・ホプキンス・ユニバーシティ タンパク質精製のための超分子フィラメント集合体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochemistry，2009年，Vol.48，doi:10.1021/bi802356k

Also Published As

Publication number Publication date
CN110741017B (zh) 2023-08-29
EP3601362A4 (en) 2020-12-16
US20260049121A1 (en) 2026-02-19
WO2018183417A1 (en) 2018-10-04
KR20230148855A (ko) 2023-10-25
US20200062827A1 (en) 2020-02-27
CN117024534A (zh) 2023-11-10
US12466875B2 (en) 2025-11-11
EP3601362A1 (en) 2020-02-05
KR20190138648A (ko) 2019-12-13
US20230050031A1 (en) 2023-02-16
JP2023011689A (ja) 2023-01-24
CN110741017A (zh) 2020-01-31
US11359005B2 (en) 2022-06-14
KR102660861B1 (ko) 2024-04-25
JP2020512385A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
JP2023011689A (ja) 生体高分子の精製のための超分子高アフィニティタンパク質結合系
US9907857B2 (en) Peptide having cell membrane penetrating activity
RU2645256C2 (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
US7098028B2 (en) Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
JP7794789B2 (ja) タンパク質精製のための超分子フィラメント集合体
US20160152686A1 (en) Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
KR20150023957A (ko) 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
CN108727486A (zh) 长效神经生长因子、制备方法及其组合物
CN107223133B (zh) 一种可溶的异质二聚t细胞受体及其制法和应用
JP5445975B2 (ja) Ｔｎｆ受容体の可溶性変異体
CN113121704B (zh) 基于纳米颗粒的冠状病毒疫苗
CN109867725A (zh) PD-1-Fc融合蛋白及其制备方法和用途
US20020151686A1 (en) Recombinant soluble adenovirus receptor
CN107365361A (zh) 与pd‑l1结合的重复域锚定蛋白及其用途
CN106957370B (zh) 一种可在肿瘤细胞内引发毒性的多肽
CN111511917A (zh) 肽结合物
CN116804062A (zh) 一种FcRn结合纳米颗粒及其用途
CN106146657B (zh) 广谱结合流感病毒a的重组抗体片段及其制备方法与应用
KR101775625B1 (ko) 혈장 내에서 안정성이 증가된 신규한 세포투과성 펩타이드 및 이것의 용도
WO2024235270A1 (zh) 补体抑制剂及其制备方法和用途
JP2024526704A (ja) 結合誘発抗体沈殿および精製のための高親和性超分子ポリマー
CN115583995A (zh) 双特异性抗体及其制备方法和应用
WO2012122519A2 (en) Ligands to the membrane protein caveolin
HK1232549B (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
WO2014019520A1 (zh) 一种肿瘤血管特异性结合多肽及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221020

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221108

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230214

R150 Certificate of patent or registration of utility model

Ref document number: 7229169

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250